Privium Fund Management B.V. Has $10.05 Million Position in ProQR Therapeutics N.V. $PRQR

Privium Fund Management B.V. boosted its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 0.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 4,997,562 shares of the biopharmaceutical company’s stock after buying an additional 11,929 shares during the period. ProQR Therapeutics makes up 2.2% of Privium Fund Management B.V.’s portfolio, making the stock its 10th largest holding. Privium Fund Management B.V. owned 4.75% of ProQR Therapeutics worth $10,045,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of PRQR. Vontobel Holding Ltd. acquired a new position in shares of ProQR Therapeutics in the first quarter valued at approximately $48,000. OneDigital Investment Advisors LLC boosted its stake in ProQR Therapeutics by 45.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 12,500 shares during the period. Persistent Asset Partners Ltd acquired a new position in ProQR Therapeutics in the 1st quarter valued at $64,000. Jane Street Group LLC grew its holdings in ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 79,720 shares in the last quarter. Finally, Monaco Asset Management SAM increased its position in ProQR Therapeutics by 59.1% during the 1st quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 175,290 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Up 9.7%

Shares of ProQR Therapeutics stock opened at $3.05 on Tuesday. ProQR Therapeutics N.V. has a 12-month low of $1.07 and a 12-month high of $4.38. The company has a market capitalization of $320.89 million, a price-to-earnings ratio of -6.63 and a beta of 0.23. The firm’s 50-day moving average price is $2.26 and its two-hundred day moving average price is $1.97.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). The firm had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%. On average, sell-side analysts expect that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current year.

Wall Street Analyst Weigh In

PRQR has been the subject of a number of recent research reports. Zacks Research cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 15th. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, August 8th. Evercore ISI restated an “outperform” rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).